Planned Solutions Inc. Makes New $2 Million Investment in Eli Lilly and Company (NYSE:LLY)

Planned Solutions Inc. purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,426 shares of the company’s stock, valued at approximately $1,997,000. Eli Lilly and Company makes up about 0.9% of Planned Solutions Inc.’s portfolio, making the stock its 17th biggest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Simon Quick Advisors LLC increased its position in Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares during the period. Liontrust Investment Partners LLP bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $8,326,000. Armstrong Fleming & Moore Inc bought a new position in Eli Lilly and Company in the 2nd quarter valued at about $357,000. Redhawk Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 0.9% in the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after buying an additional 65 shares during the period. Finally, Assenagon Asset Management S.A. increased its holdings in Eli Lilly and Company by 4.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 474,940 shares of the company’s stock valued at $255,105,000 after buying an additional 18,079 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 14,388 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $630.28, for a total value of $9,068,468.64. Following the transaction, the insider now owns 99,754,422 shares in the company, valued at $62,873,217,098.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 195,055 shares of company stock worth $125,254,657 over the last ninety days. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on LLY shares. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st. Finally, Barclays boosted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $689.52.

Eli Lilly and Company Trading Up 0.5 %

Shares of Eli Lilly and Company stock opened at $778.69 on Thursday. Eli Lilly and Company has a 12-month low of $334.58 and a 12-month high of $800.78. The company has a market cap of $739.88 billion, a price-to-earnings ratio of 134.26, a PEG ratio of 1.70 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company’s 50-day moving average price is $727.96 and its 200-day moving average price is $636.01.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.09 earnings per share. On average, equities analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.